GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
This article was originally published in The Rose Sheet
Executive Summary
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
You may also be interested in...
NanoBio, GSK Leave Rx Drug Path To Take "Remarkable" Cold Sore Med OTC
Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow, aiming straight for the OTC market with the help of GlaxoSmithKline
NanoBio, GSK Leave Rx Drug Path To Take "Remarkable" Cold Sore Med OTC
Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow, aiming straight for the OTC market with the help of GlaxoSmithKline
C&D’s Act May Be Hard To Follow For Drug Firms Considering Bolt-Ons
Church & Dwight CEO James Craigie has a few words of wisdom on bolt-on acquisitions, recently a popular buzzword among big pharmas looking for savings